Hepatitis
Clinical trial results of oral hepatitis C RNA polymerase inhibitor released
Published in Vaccine Weekly, December 22nd, 2004
The two-center, double-blind, dose-escalation study examined the safety and pharmacokinetics of R803 and its effectiveness in reducing viral levels in 32 patients infected with hepatitis C virus (HCV). The results demonstrated that R803 was well tolerated and that there were no significant adverse effects.
The study showed that the drug was only present in the blood stream at sufficient levels for a limited number of hours during the course of each dosing day. There was a decline in viral...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
Source: Vaccine Weekly (2004-12-22)
More Articles from Vaccine Weekly
- Anthrax Vaccine
Human immune response to U.K. anthrax vaccine characterized - Leishmaniasis Vaccine
Leishmania antigen and ODN protect against L. donovani infection - Meningococcal Vaccine
P64k meningococcal protein elicited cell-mediated immune response in mice - Neisseria Vaccine
Functional genomics applied to Neisseria meningitides vaccine development - AIDS/HIV Pathogenesis
DC-SIGN interference inhibits HIV transmission from dendritic to T cells - AIDS/HIV Vaccine
Disease-modifying HIV vaccines could increase epidemic severity - More from this issue of Vaccine Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
